RESUMO
A 48-year-old woman presented to the emergency department with a one-week history of progressive dyspnea. During her hospitalization, the diagnosis of diffuse alveolar hemorrhage was made. She subsequently developed respiratory failure and acute right ventricular failure. Despite medical treatment, she continued to experience distributive shock due to a generalized inflammatory response. Circulatory support with ECMO was needed. We opted for triple cannulation to manage the multiorgan failure as a bridge to recovery. We describe our experience with an uncommon cannulation technique: veno-pulmonary-arterial cannulation, which enabled us to address cardiogenic shock, refractory hypoxemia, and distributive shock, leading to the successful recovery of the patient.
RESUMO
Objectives: Percutaneous pulmonary artery cannulas, used as inflow for left ventricular venting or as outflow for right ventricular mechanical circulatory support, are easily and rapidly deployable with transesophageal and fluoroscopic guidance. Methods: We chose to review our institutional and technical experience with all right atrium to pulmonary artery cannulations. Results: Based on the review, we describe 6 right atrium to pulmonary artery cannulation strategies. They are divided into total right ventricular assist support, partial right ventricular assist support, and left ventricular venting. A single limb cannula or a dual lumen cannula can be used for right ventricular support. Conclusions: In the right ventricular assist device configuration, percutaneous cannulation may prove beneficial in cases of isolated right ventricular failure. Conversely, pulmonary artery cannulation can be used for left ventricular venting as drainage to a cardiopulmonary bypass or extracorporeal membrane oxygenation circuit. This article can be used as a reference for the technical aspects of cannulation, decision-making in patient selection, and management of patients in these clinical scenarios.
RESUMO
OBJECTIVE: To describe the incidence and predictors of acute limb ischemia (ALI) in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS). METHODS: Patients with index hospitalizations for AMI complicated by cardiogenic shock from 2016 to 2019 in the US National Readmission Database were identified. We evaluated the incidence of ALI and its associated mortality, length of stay, and cost of hospitalization. We used multivariable logistic regression to determine independent predictors of ALI in this population. RESULTS: A total of 84,615 patients had AMI complicated by cardiogenic shock and 1302 (1.54%) developed ALI. The rates of ALI increased from 1.29% in 2016 to 1.66% in 2019 (P ≤ .002). The use of microaxial mechanical circulatory support increased from 2.25% in 2016 to 13.36% in 2019 (P = .0001). The major predictors of ALI included peripheral arterial disease (odds ratio [OR], 7.34; 95% confidence interval [CI], 6.12-8.81), venoarterial extracorporeal membrane oxygenation (OR, 4.40; 95% CI, 3.19-6.07), and microaxial mechanical circulatory support (OR, 3.12; 95% CI, 2.74-3.55). ALI in patients with cardiogenic shock was associated higher mortality (39.20% vs 33.53%; P ≤ .0001). CONCLUSIONS: This nationwide observational study shows that ALI is an important complication of AMI with cardiogenic shock. This complication is associated with higher mortality. In addition to peripheral artery disease, the use of mechanical circulatory devices was associated with significantly higher rates of ALI.
Assuntos
Coração Auxiliar , Infarto do Miocárdio , Doença Arterial Periférica , Humanos , Choque Cardiogênico , Incidência , Resultado do Tratamento , Mortalidade Hospitalar , Doença Arterial Periférica/complicações , Coração Auxiliar/efeitos adversos , Estudos RetrospectivosRESUMO
AIMS: Treatment with mechanical circulatory support (MCS) has been proposed to mitigate mortality in cardiogenic shock (CS). However, there is a lack of data on MCS programs implementation and the effect of the learning curve on its outcomes in limited resources countries such as Brazil. METHODS: Prospective cohort of patients with CS admitted in four tertiary-care centers treated with Impella CP or veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Clinical outcomes were peri-procedural complications, short-term mortality rate, and the centers' learning curve. The cohort was divided into two periods: from April 2017 to July 2018 (n = 24), and from August 2018 to December 2020 (n = 25). RESULTS: The study enrolled 49 patients [age 59 (43-63) years; 34 (70%) males]. The most common causes for CS were acute myocardial infarction in 22 (45%) and acute decompensation of chronic heart failure in 10 (20%). VA-ECMO was employed in 35 (71%) and Impella CP in 14 (29%) of patients. Overall complications occurred in 37 (76%) of patients, where major bleeding in 19 (38%) was the most common. The overall mortality rate was 61%, but it was lower in the second period (40%) in comparison to the first period (83%), p = 0.002. The learning curve analysis showed a decrease in the mortality rate after 40 consecutive cases. CONCLUSIONS: Implementation of a temporary MCS program for refractory CS in a limited resource country is feasible. The learning curve effect might have played a role on survival rate since high morbimortality has decreased within time reaching optimal results by the end of the study.
Assuntos
Coração Auxiliar , Choque Cardiogênico , Brasil , Coração Auxiliar/efeitos adversos , Humanos , Curva de Aprendizado , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Choque Cardiogênico/etiologia , Resultado do TratamentoRESUMO
BACKGROUND: To evaluate the prognostic value of peak serum lactate and lactate clearance at several time points in cardiogenic shock treated with temporary mechanical circulatory support (MCS) using veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or Impella CP®. METHODS: Serum lactate and clearance were measured before MCS and at 1 h, 6 h, 12 h, and 24 h post-MCS in 43 patients at four tertiary-care centers in Southern Brazil. Prognostic value was assessed by univariable and multivariable analysis and receiver operating characteristic (ROC) curves for 30-day mortality. RESULTS: VA-ECMO was the most common MCS modality (58%). Serum lactate levels at all time points and lactate clearance after 6 h were associated with mortality on unadjusted and adjusted analyses. Lactate levels were higher in non-survivors at 6 h, 12 h, and 24 h after MCS. Serum lactate > 1.55 mmol/L at 24 h was the best single prognostic marker of 30-day mortality [area under the ROC curve = 0.81 (0.67-0.94); positive predictive value = 86%). Failure to improve serum lactate after 24 h was associated with 100% mortality. CONCLUSIONS: Serum lactate was an important prognostic biomarker in cardiogenic shock treated with temporary MCS. Serum lactate and lactate clearance at 24 h were the strongest independent predictors of short-term survival.
Assuntos
Oxigenação por Membrana Extracorpórea , Ácido Láctico/sangue , Implantação de Prótese , Choque Cardiogênico/terapia , Adulto , Biomarcadores/sangue , Brasil , Oxigenação por Membrana Extracorpórea/efeitos adversos , Oxigenação por Membrana Extracorpórea/instrumentação , Oxigenação por Membrana Extracorpórea/mortalidade , Feminino , Coração Auxiliar , Humanos , Masculino , Pessoa de Meia-Idade , Oxigenadores de Membrana , Valor Preditivo dos Testes , Implantação de Prótese/efeitos adversos , Implantação de Prótese/instrumentação , Implantação de Prótese/mortalidade , Estudos Retrospectivos , Fatores de Risco , Choque Cardiogênico/sangue , Choque Cardiogênico/diagnóstico , Choque Cardiogênico/mortalidade , Fatores de Tempo , Resultado do TratamentoRESUMO
Intra-aortic balloon counterpulsation (IAoBC) is a mechanical circulatory support device that has been used for more than 50 years, mainly for cardiogenic shock. Although its effect on mortality is controversial, IAoBC is still used in a wide variety of pre- and postoperative clinical settings in cardiac surgery centers. IAoBC has a complication rate of approximately 30%, mostly associated with problems during insertion and malpositioning. Thus, an insertion technique based on the use of ultrasound at the patient's bedside in the intensive care unit (ICU) is proposed.
RESUMO
This study presents an assessment for long-term use of the apical aortic blood pump (AABP), focusing on wear reduction in the bearing system. AABP is a centrifugal left ventricle assist device initially developed for bridge to transplant application. To analyze AABP performance in long-term applications, a durability test was performed. This test indicated that wear in the lower bearing pivot causes device failure in long-term. A wear test in the bearing system was conducted to demonstrate the correlation of the load in the bearing system with wear. Results from the wear test showed a direct correlation between load and wear at the lower bearing pivot. In order to reduce load, thus reducing wear, a new stator topology has been proposed. In this topology, a radial stator would replace the axial stator previously used. Another durability test with the new stator has accounted twice the time without failure when compared with the original model.
Assuntos
Coração Auxiliar , Aorta/fisiologia , Análise de Falha de Equipamento , Coração Auxiliar/efeitos adversos , Humanos , Desenho de Prótese , Falha de Prótese , Fatores de TempoRESUMO
La insuficiencia cardíaca (IC) continúa siendo una enfermedad de alta prevalencia, afectando al 1-2% de la población en países desarrollados y constituye por ello un problema de salud por los altos costos que esto conlleva. A pesar de los avances en el tratamiento farmacológico y mediante dispositivos implantables presenta un pronóstico pobre. Aproximadamente un 5% de los pacientes con diagnóstico de IC se hallan en un estadio avanzado de la enfermedad o estadio D. En las últimas tres décadas el trasplante cardíaco (TC) se ha convertido en el tratamiento de elección para este grupo de altísimo riesgo. Desafortunadamente, un pequeño porcentaje de pacientes cumple con la edad adecuada y con la ausencia de comorbilidades necesarias para poder acceder a este tratamiento, además de la limitante de la escasez de donantes en la actualidad. Debido a ello y a las largas listas de espera a nivel mundial, cada vez es mayor el desarrollo y la utilización de dispositivos de asistencia ventricular (DAV), que han mejorado la supervivencia a corto y largo plazo, dada la calidad de vida de pacientes con esta grave afección, generando una reducción progresiva de la tasa de complicaciones. Estos beneficios no solo aportan una alternativa a pacientes que esperan un TC, sino que permiten a aquellos con contraindicaciones reversibles a disponer del tiempo y la oportunidad de convertirse en candidatos adecuados, o en caso de que esto no sea posible, su final utilización como terapia de destino. Aun así son muchas las limitaciones de estos dispositivos: su costo, su durabilidad, la tasa de complicaciones y su aplicación a un espectro limitado de pacientes. El avance tecnológico para paliar las complicaciones, la mayor experiencia en los centros de manejo y su generalización para permitir un costo más reducido son estrategias que permitirán que la utilización de DAV en los pacientes con IC avanzada se continúe afianzando.
Heart failure (HF) continues to be a highly prevalent disease, affecting 1-2% of the population in developed countries and is therefore a health problem due to the high costs that this entails. Despite advances in pharmacological treatment and implantable devices, it has a poor prognosis. Approximately 5% of patients diagnosed with HF are in an advanced stage of the disease or stage D. In the last three decades, heart transplantation (HT) has become the treatment of choice for this group of very high risk. Unfortunately, a small percentage of patients meet the appropriate age and the absence of comorbidities necessary to access this treatment, in addition to the limitation of the shortage of donors at present. Due to this and the long waiting lists worldwide, the development and use of ventricular assist devices (VAD), which have improved short and long-term survival, due to the quality of life of patients with This serious condition, generating a progressive reduction in the rate of complications. These benefits not only provide an alternative for patients waiting for a HT, but also allow those with reversible contraindications to have the time and opportunity to become suitable candidates, or in case this is not possible, their final use as therapy of destiny. Even so, there are many limitations of these devices: their cost, their durability, the rate of complications and their application to a limited spectrum of patients. The technological advance to alleviate the complications, the greater experience in the centers of management and its generalization to allow a lower cost are strategies that will allow the use of VAD in patients with advanced HF to continue strengthening.
A insuficiência cardíaca (IC) continua a ser uma doença altamente prevalente, afetando 1-2% da população nos países desenvolvidos e, portanto, é um problema de saúde devido aos altos custos que isso acarreta. Apesar dos avanços no tratamento farmacológico e dispositivos implantáveis, tem um mau prognóstico. Aproximadamente 5% dos pacientes com diagnóstico de IC estão em estágio avançado da doença ou estágio D. Nas últimas três décadas, o transplante cardíaco (TC) tornou-se o tratamento de escolha para esse grupo de risco muito alto. Infelizmente, uma pequena porcentagem de pacientes atinge a idade adequada e a ausência de comorbidades necessárias para acessar esse tratamento, além da limitação da falta de doadores no momento. Devido a isso e as longas listas de espera em todo o mundo, o desenvolvimento e uso de dispositivos de assistência ventricular (DAV), que melhoraram a sobrevivência a curto e longo prazo, devido à qualidade de vida dos pacientes com Esta condição séria, gerando uma redução progressiva na taxa de complicações. Esses benefícios não apenas fornecem uma alternativa para pacientes que aguardam um TC, mas também permitem que aqueles com contraindicações reversíveis tenham tempo e oportunidade de se tornarem candidatos adequados ou, caso isso não seja possível, seu uso final como terapia. de destino. Mesmo assim, existem muitas limitações desses dispositivos: seu custo, sua durabilidade, a taxa de complicações e sua aplicação a um espectro limitado de pacientes. O avanço tecnológico para aliviar as complicações, a maior experiência nos centros de gestão e sua generalização para permitir um menor custo são estratégias que permitirão que o uso do DAV em pacientes com IC avançada continue fortalecendo-se.
RESUMO
PURPOSE OF REVIEW: Chagas cardiomyopathy is a major public health disease in Latin America and, due to migration, is becoming a worldwide health and economic burden. This review sought to present the clinical and epidemiological aspects of Chagas cardiomyopathy, as well as some specific features and principles of treatment. We also retrospectively assessed our institutional experience with mechanical circulatory support in refractory heart failure due to Chagas cardiomyopathy over a 10-year period. RECENT FINDINGS: The role of antiparasitic treatment in patients with heart failure due to Chagas cardiomyopathy is controversial. Heart transplantation, although formerly contraindicated, is currently established as an important therapeutic option. Also, the favorable characteristics of Chagas patients, such as younger age, little comorbidity, and no reoperations or severe pulmonary hypertension, could be an advantage for a mechanical circulatory support indication in advanced heart failure due to Chagas cardiomyopathy. Despite the absence of large evidence-based data, much has been accomplished since Carlos Chagas' discovery one century ago. Our institutional experience shows that mechanical circulatory support in Chagas patients is associated with more successful bridging to heart transplantation when compared to non-Chagas patients.
Assuntos
Cardiomiopatia Chagásica/cirurgia , Doença de Chagas/complicações , Insuficiência Cardíaca/parasitologia , Transplante de Coração , Cardiomiopatia Chagásica/etiologia , Cardiomiopatia Chagásica/parasitologia , Doença de Chagas/parasitologia , Insuficiência Cardíaca/cirurgia , Humanos , América Latina , Estudos Retrospectivos , Trypanosoma cruziRESUMO
BACKGROUND: There are limited options for percutaneous mechanical circulatory support (pMCS) in patients requiring high-risk percutaneous coronary intervention. OBJECTIVES: This first-in-human, single-center study aimed to evaluate the safety and feasibility of a novel pMCS device in high-risk percutaneous coronary intervention patients. METHODS: Aortix (Procyrion, Houston, Texas) is a pMCS device deployed in the descending aorta via the femoral artery that uses axial flow to provide cardiac unloading and augment renal and systemic perfusion. We assessed the use and effect of the Aortix device in six patients undergoing high-risk PCI. All patients had impaired left ventricular function, complex coronary disease, renal dysfunction, and suitable iliofemoral anatomy for Aortix placement via transfemoral approach. We recorded periprocedural events including hemodynamic effects of the device on cardiac output and urine output. We then followed patients up to 30 days following the PCI procedure for adverse events. RESULTS: Aortix delivery (18 Fr sheath) took 4-9 min, mean support time was 70 (range 47-95) min, and mean flow rate through the device was 3.5 L/min. During support, mean rate of urine output increased 10-fold (range 2.5-25.0x). Estimated GFR improved at discharge compared with baseline (mean increase 6.95 ± 8.09 mL/min). There were no device failures and PCI was successful in all patients. Aortix was removed and hemostasis was achieved with a vascular closure device and manual pressure. No patients experienced adverse events or hemodynamic compromise. No clinically significant hemolysis occurred (mean LDH 239.2 ± 73.6 mU/mL at baseline and 206.4 ± 82.2 mU/mL at discharge). No vascular access complications were observed. CONCLUSIONS: Aortix, a novel pMCS device, was successfully deployed and retrieved in all initial patients undergoing high-risk PCI. We noted no significant hemolysis with temporary use of this axial flow device. Improvement in eGFR suggests a potential renal protective effect and is an important area for future investigation in patients with impaired left ventricular function and renal dysfunction.
Assuntos
Aorta/fisiopatologia , Doença da Artéria Coronariana/terapia , Coração Auxiliar , Intervenção Coronária Percutânea , Implantação de Prótese/instrumentação , Disfunção Ventricular Esquerda/terapia , Idoso , Doença da Artéria Coronariana/diagnóstico , Doença da Artéria Coronariana/fisiopatologia , Circulação Coronária , Remoção de Dispositivo , Estudos de Viabilidade , Feminino , Taxa de Filtração Glomerular , Hemodinâmica , Humanos , Rim/fisiopatologia , Nefropatias/fisiopatologia , Masculino , Pessoa de Meia-Idade , Paraguai , Intervenção Coronária Percutânea/efeitos adversos , Estudos Prospectivos , Desenho de Prótese , Implantação de Prótese/efeitos adversos , Recuperação de Função Fisiológica , Fluxo Sanguíneo Regional , Circulação Renal , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Micção , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/fisiopatologia , Função Ventricular EsquerdaAssuntos
Anomalia de Ebstein/diagnóstico por imagem , Cardiopatias Congênitas/diagnóstico por imagem , Insuficiência Cardíaca/diagnóstico por imagem , Insuficiência Cardíaca/cirurgia , Coração Auxiliar , Imagem Multimodal/métodos , Adolescente , Anomalia de Ebstein/complicações , Ecocardiografia Doppler/métodos , Eletrocardiografia/métodos , Serviço Hospitalar de Emergência , Seguimentos , Cardiopatias Congênitas/complicações , Insuficiência Cardíaca/etiologia , Humanos , Masculino , Alta do Paciente , Radiografia Torácica/métodos , Medição de Risco , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
The aim of this systematic review and meta-analysis was to evaluate the outcomes of concomitant mitral valve surgery for significant preexisting mitral regurgitation (MR) in patients undergoing continuous-flow left ventricular assist device (CF-LVAD) implantation. Electronic search was performed to identify all studies in the English literature examining concurrent mitral valve surgery in patients with CF-LVAD implantation. Identified articles were systematically assessed for inclusion and exclusion criteria. Of 2319 studies identified, 8 studies were included. Among 445 patients with moderate to severe or severe MR, 113 (25.4%) patients received concurrent mitral valvular intervention during CF-LVAD implantation. There were no significant differences in cardiopulmonary bypass time (MR Surgery 154 min vs. no MR Surgery 119 min, P = 0.64) or hospital length of stay (MR Surgery 21 days vs. no MR Surgery 18 days, P = 0.93). On follow-up, there were no significant differences in freedom from greater than moderate MR (MR Surgery 100% vs. no MR Surgery 74%, P = 0.12) or left ventricular end-diastolic diameter (MR Surgery: 60 mm vs. no MR Surgery 65 mm, P = 0.51). Survival was comparable at 6-months (MR Surgery 77% vs. no MR Surgery 81%, P = 0.75), 1-year (MR Surgery 72% vs. no MR Surgery 80%, P = 0.36), and 2-years of follow-up (MR Surgery 65% vs. no MR Surgery 70%, P = 0.56). The results of our systematic review and meta-analysis of 8 studies consisting of 445 patients demonstrates that the addition of mitral valve intervention to CF-LVAD implantation appears to be safe with comparable survival to those undergoing CF-LVAD implantation alone. Large prospective randomized clinical trials are needed to elucidate whether concomitant mitral valve intervention during CF-LVAD implantation in patients with severe MR is necessary.
Assuntos
Insuficiência Cardíaca/cirurgia , Coração Auxiliar , Insuficiência da Valva Mitral/cirurgia , Valva Mitral/cirurgia , Implantação de Prótese/mortalidade , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/mortalidade , Humanos , Insuficiência da Valva Mitral/complicações , Insuficiência da Valva Mitral/mortalidadeAssuntos
Procedimentos Cirúrgicos Cardiovasculares/métodos , Medicina Baseada em Evidências/métodos , Balão Intra-Aórtico/métodos , Assistência Perioperatória/métodos , Anestesiologistas/tendências , Procedimentos Cirúrgicos Cardiovasculares/tendências , Medicina Baseada em Evidências/tendências , Humanos , Balão Intra-Aórtico/tendências , Infarto do Miocárdio/diagnóstico por imagem , Infarto do Miocárdio/cirurgia , Assistência Perioperatória/tendências , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Choque Cardiogênico/diagnóstico por imagem , Choque Cardiogênico/cirurgiaRESUMO
BACKGROUND: Nonsurgical bleeding is a frequent complication of continuous-flow left ventricular assist device (LVAD) support. Abnormal von Willebrand factor (vWF) metabolism plays a major role. However, the relationship between LVAD speed and vWF degradation is unknown. Recent evidence has demonstrated that supraphysiologic shear stress from continuous-flow LVADs accelerates vWF degradation and causes an acquired vWF deficiency and bleeding. To manage LVAD-associated bleeding, it has been proposed that reduced LVAD speed may decrease shear stress and thereby reduce pathologic vWF metabolism. However, there are little published data to support this clinical practice. We tested the hypothesis that reduced continuous-flow LVAD speed decreases vWF degradation. METHODS: Whole blood was collected from patients before and after the implantation of a HeartMate II continuous-flow LVAD (n = 10) to quantify in vivo vWF degradation. In parallel, to evaluate the relationship between LVAD rpm and vWF degradation, whole blood was collected from human donors (n = 30). Single-donor units of blood circulated in an ex vivo HeartMate II mock circulatory loop for 12 hours at 11,400, 10,000, or 8600 rpm (n = 10/each rpm group). vWF multimers and degradation fragments were characterized with electrophoresis and immunoblot analysis. Paired Student t tests were performed within each group. ANOVA with Tukey post hoc test was performed across groups. RESULTS: In patients, LVAD support reduced large vWF multimers and significantly (P < .05) increased vWF degradation fragments. The profile of vWF degradation was nearly identical between LVAD patients and blood circulated in the LVAD mock circulatory loop. At 11,400, 10,000, and 8600 rpm, decreased large vWF multimers and significantly increased vWF degradation fragments were noted. vWF degradation fragments were not statistically different across the 3 rpm groups or versus LVAD patients, which suggested that LVAD rpm did not influence vWF degradation. CONCLUSIONS: Reduced LVAD speed (within the clinical operational range) did not significantly decrease vWF degradation in a mock circulatory loop with human blood. During bleeding events, reduced LVAD speed, itself, may not diminish vWF degradation.
Assuntos
Insuficiência Cardíaca/terapia , Coração Auxiliar , Doenças de von Willebrand/sangue , Fator de von Willebrand/análise , Adulto , Idoso , Eletroforese em Gel de Poliacrilamida , Feminino , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Estresse Mecânico , Doenças de von Willebrand/etiologiaRESUMO
La insuficiencia cardiaca constituye una verdadera epidemia a nivel mundial, y Chile no es la excepción. Como respuesta, la medicina ha ido ofreciendo un número cada vez mayor de alternativas para enfrentarla, con mejoras significativas en el tratamiento farmacológico, dispositivos de resincronización cardiaca y diferentes alternativas quirúrgicas, todo lo cual ha mejorado la sintomatología y ha prolongado parcialmente la supervivencia de esta patología en las fases iniciales. Sin embargo en las fases más avanzadas de esta enfermedad, sólo el trasplante cardiaco y actualmente la asistencia circulatoria, han demostrado una mejoría significativa de la supervivencia de este complejo grupo de pacientes. En esta revisión, intentamos revisar en profundidad los aspectos epidemiológicos, clínicos y terapéuticos en el enfrentamiento de esta patología, haciendo hincapié en diferentes aspectos quirúrgicos y en la indicación y manejo de la asistencia circulatoria mecánica, aspectos que son fundamentales a la hora de usar en forma segura esta nueva tecnología.
Heart failure is an epidemic worldwide disease, affecting mainly developed countries. In response, medicine has been offering an increasing number of treatment alternatives with significant improvements in drug therapy, cardiac resynchronization devices and surgical alternatives, all of which have improved symptoms and prolonged survival in the early stages of this pathology. However, in final stages, only heart transplantation has shown significant improvement in survival, and in the last years, Mechanical Circulatory Assistance has shown good results in this complex group of patients. In this article we review epidemiological, clinical and therapeutic aspects of Mechanical Circulatory Support, emphasizing on indications and contraindications, management, quality assurance and education of this therapeutic alternative for heart failure.
Assuntos
Humanos , Circulação Assistida , Transplante de Coração , Coração Auxiliar , Insuficiência Cardíaca/terapiaRESUMO
La insuficiencia cardiaca es considerada una de las enfermedades más prevalente de los últimos años. A pesar de los avances para su tratamiento con las nuevas drogas y dispositivos, como el cardiodesfibrilador implantable y la terapia de resincronización cardiaca, la progresión lleva a deterioro en la calidad de vida, frecuentes hospitalizaciones y altos porcentajes de mortalidad. En la etapa avanzada de esta enfermedad el trasplante cardiaco continua siendo de elección para su tratamiento, aunque no constituye la terapia adecuada para todos los pacientes. Muchos a la espera del mismo requieren soporte con drogas inotrópicas las cuales conllevan a deterioro progresivo y supervivencia limitada, cuando los tiempos de espera se prolongan o el trasplante no se realiza. Por esto, los avances en asistidores mecánicos permiten considerar a estos dispositivos como el tratamiento durante la espera del trasplante y como una alternativa en los cuales el trasplante no se considera una opción. Es nuestro objetivo realizar una revisión sobre los avances y la utilidad de los asistidores mecánicos en los pacientes con insuficiencia cardiaca avanzada, en los cuales la última opción es el trasplante cardiaco.
Heart failure is considering one of the most prevalent diseases in recent years. Despite advances in the treatment with new drugs and devices such as implantable defibrillator and cardiac resynchronization therapy, the progression in heart failure leads to deterioration in the quality of life, frequent hospitalizations and high mortality rates. Advanced stage of this disease remains heart transplantation for treatment choice, although is not the adequate therapy for all the patients. Many of them require support with inotropic drugs, which lead to a progressive deterioration and limited survival, because waiting times are prolonged or transplantation is not performed. Therefore, progress in circulatory support devices allow to consider these as the treatment while awaiting transplantation and an alternative when the transplant is not considered an option. It is our objective to review the progress and the usefulness of circulatory support devices in patients with advanced heart failure, in which the last option is heart transplantation.